SDAMLO (amlodipine) by BrilliantStrings Therapeutics is (calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. First approved in 2025.
Drug data last refreshed 2h ago · AI intelligence enriched 1w ago
SDAMLO (amlodipine) is a calcium channel antagonist approved as an oral solution for treating hypertension and angina. It works by inhibiting calcium ion influx into vascular smooth muscle and cardiac muscle, reducing peripheral vascular resistance and blood pressure while improving coronary blood flow. The drug is particularly effective in vasospastic angina by preventing coronary artery constriction.
As a newly launched generic formulation with moderate competitive pressure (30%), this product offers entry-level and growth opportunities in a stable, established therapeutic category with potential for rapid team expansion.
(calcium ion antagonist or slow-channel blocker) that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. Experimental data suggest that amlodipine binds to both dihydropyridine and nondihydropyridine binding sites. The contractile processes of cardiac…
Worked on SDAMLO at BrilliantStrings Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Bioequivalence Study of Amlodipine/Valsartan 10/160 mg Film Coated Tablets
Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
Study of Efficacy and Safety of LCZ696/Amlodipine in Grade 1 and 2 Hypertension Patients Uncontrolled by LCZ696 Monotherapy
Description of the Effectiveness, Safety, Tolerability and Adherence to Amlodipine/Atorvastatin/Perindopril Single Pill Combination Treatment in Patients With Arterial Hypertension and Dyslipidemia (TARGET)
S-amlodipine in Essential HypertensIon and Assessment of Blood Pressure Targets Achievement
Working on SDAMLO offers entry and mid-level career paths in a launch-phase generic product within a stable, well-understood therapeutic category. Success depends on rapid market penetration and competitive positioning against established amlodipine brands in a price-sensitive market.